A Abbott Labs
| Market Cap | $178.76B |
| P/E Ratio | 27.65 |
| Forward P/E | 16.85 |
| Dividend Yield | 2.45% |
| Beta | 0.78 |
| 52W Range | $101.88 - $136.16 |
| # Hedge Funds | 8 |
| Sector | Healthcare |
| Industry | Medical Devices |
Hedge Fund Ownership
| Investor 8 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Jensen Investment Management Jensen Investment Management | 3.69% | $234.68M | 1,873,063 | Reduce 22.26% |
| Polen Capital Management Polen Capital Management | 2.12% | $496.43M | 3,962,230 | Reduce 46.61% |
| Mairs & Power Growth Fund Mairs & Power Inc | 0.85% | $88.72M | 708,081 | Reduce 2.05% |
| FPA Queens Road Small Cap Value Fund Bragg Financial Advisors | 0.45% | $13.96M | 111,462 | Add 0.59% |
| Torray Funds Torray Investment Partners | 0.03% | $225.00K | 1,800 | — |
| Thomas Russo Gardner Russo & Quinn | 0.02% | $1.44M | 11,510 | — |
| Dodge & Cox Dodge & Cox | 0.00% | $2.17M | 17,324 | — |
| Bill Nygren Harris Associates LP | 0.00% | $256.00K | 2,046 | — |
Insider Trading
| Insider Name of the company insider who made the trade 13 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Cushman Elizabeth C.EVP, GC AND SECRETARY | Sale | 263 | $115.58 | $30.40K | 02 Mar 2026 | 03 Mar 2026 |
| MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLER | Sale | 585 | $115.58 | $67.61K | 02 Mar 2026 | 03 Mar 2026 |
| Shroff EricSenior Vice President | Sale | 709 | $115.58 | $81.95K | 02 Mar 2026 | 03 Mar 2026 |
| Moreland Mary KEXECUTIVE VICE PRESIDENT | Sale | 613 | $115.58 | $70.85K | 02 Mar 2026 | 03 Mar 2026 |
| Morrone Louis H.EXECUTIVE VICE PRESIDENT | Sale | 1,144 | $115.58 | $132.22K | 02 Mar 2026 | 03 Mar 2026 |
| Salvadori Daniel Gesua SiveEVP AND GROUP PRESIDENT | Sale | 885 | $115.58 | $102.29K | 02 Mar 2026 | 03 Mar 2026 |
| STARKS DANIEL J | Buy | 4,967 | $109.14 | $542.09K | 04 Feb 2026 | 06 Feb 2026 |
| STARKS DANIEL J | Buy | 5,033 | $108.33 | $545.24K | 04 Feb 2026 | 06 Feb 2026 |
| Daniel J StarksDirector | Buy | 4,967 | $109.14 | $542.09K | 04 Feb 2026 | 06 Feb 2026 |
| Daniel J StarksDirector | Buy | 5,033 | $108.33 | $545.24K | 04 Feb 2026 | 06 Feb 2026 |
| Ford Robert BCHAIRMAN AND CEO | Buy | 18,800 | $107.13 | $2.01M | 23 Jan 2026 | 26 Jan 2026 |
| Shroff EricSenior Vice President | Sale | 1,586 | $128.02 | $203.04K | 25 Nov 2025 | 25 Nov 2025 |
| Eric ShroffSenior Vice President | Sale | 1,586 | $128.02 | $203.04K | 25 Nov 2025 | 25 Nov 2025 |
Frequently Asked Questions
What is ABT stock price today?
Abbott Labs (ABT) is currently trading at $102.87. The stock has a 52-week range of $101.88 to $136.16 and a market capitalization of $178.76B.
Is ABT a good stock to buy in 2026?
Abbott Labs has a P/E ratio of 27.7 (forward P/E: 16.9), a dividend yield of 2.45%, and 1-year performance of -20.4%. 8 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling ABT stock?
There have been 13 insider transactions for ABT in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has ABT stock performed over the past year?
Abbott Labs (ABT) has returned -20.4% over the past 12 months. The stock traded between $101.88 and $136.16 during this period, and is currently at $102.87.
Which hedge funds own ABT (Abbott Labs)?
8 tracked hedge funds currently hold ABT in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is ABT's market cap and valuation?
Abbott Labs (ABT) has a market capitalization of $178.76B. The trailing P/E ratio is 27.7 and forward P/E is 16.9. The stock is classified in the Healthcare sector.
What is ABT's revenue and profitability?
Abbott Labs reported revenue of $44.33B with net income of $6.50B and a profit margin of 0.15%. The stock has a beta of 0.78.
What sector is ABT in and who are its biggest institutional holders?
Abbott Labs (ABT) operates in the Healthcare sector. It is held by 8 tracked hedge funds. See the ownership table above for the complete list.